Mol. Cells 2012; 34(4): 393-398
Published online September 13, 2012
https://doi.org/10.1007/s10059-012-0177-0
© The Korean Society for Molecular and Cellular Biology
Correspondence to : *Correspondence: hyungseok.choi@lge.com
Breast cancer is a clinically heterogeneous disease char-acterized by distinct molecular aberrations. Under-standing the heterogeneity and identifying subgroups of breast cancer are essential to improving diagnoses and predicting therapeutic responses. In this paper, we pro-pose a classification scheme for breast cancer which integrates data on differentially expressed genes (DEGs), copy number variations (CNVs) and microRNAs (miRNAs)-regulated mRNAs. Pathway information based on the estimation of molecular pathway activity is also applied as a postprocessor to optimize the classifier. A total of 250 malignant breast tumors were analyzed by k-means clustering based on the patterns of the expression profiles of 215 intrinsic genes, and the classification performances were compared with existing breast cancer classifiers including the BluePrint and the 625-gene classifier. We show that a classification scheme which incorporates pathway information with various genetic variations achieves better per-formance than classifiers based on the expression levels of individual genes, and propose that the identified signature serves as a basic tool for identifying rational therapeutic opportunities for breast cancer patients.
Keywords breast cancer, classification, copy number variation, differentially expressed gene, microRNA, pathway
Mol. Cells 2012; 34(4): 393-398
Published online October 31, 2012 https://doi.org/10.1007/s10059-012-0177-0
Copyright © The Korean Society for Molecular and Cellular Biology.
Hae-Seok Eo, Jee Yeon Heo, Yongjin Choi, Youngdon Hwang, and Hyung-Seok Choi*
Bio&Health Team, Future IT R&D Laboratory, LGE Advanced Research Institute, Seoul 137-724, Korea
Correspondence to:*Correspondence: hyungseok.choi@lge.com
Breast cancer is a clinically heterogeneous disease char-acterized by distinct molecular aberrations. Under-standing the heterogeneity and identifying subgroups of breast cancer are essential to improving diagnoses and predicting therapeutic responses. In this paper, we pro-pose a classification scheme for breast cancer which integrates data on differentially expressed genes (DEGs), copy number variations (CNVs) and microRNAs (miRNAs)-regulated mRNAs. Pathway information based on the estimation of molecular pathway activity is also applied as a postprocessor to optimize the classifier. A total of 250 malignant breast tumors were analyzed by k-means clustering based on the patterns of the expression profiles of 215 intrinsic genes, and the classification performances were compared with existing breast cancer classifiers including the BluePrint and the 625-gene classifier. We show that a classification scheme which incorporates pathway information with various genetic variations achieves better per-formance than classifiers based on the expression levels of individual genes, and propose that the identified signature serves as a basic tool for identifying rational therapeutic opportunities for breast cancer patients.
Keywords: breast cancer, classification, copy number variation, differentially expressed gene, microRNA, pathway
Min Ji Park, Eunji Jeong, Eun Ji Lee, Hyeon Ji Choi, Bo Hyun Moon, Keunsoo Kang, and Suhwan Chang
Mol. Cells 2023; 46(6): 351-359 https://doi.org/10.14348/molcells.2023.2174Hyeonseo Hwang, Hee Ryung Chang, and Daehyun Baek
Mol. Cells 2023; 46(1): 21-32 https://doi.org/10.14348/molcells.2023.2157Chaehwan Oh, Dahyeon Koh, Hyeong Bin Jeon, and Kyoung Mi Kim
Mol. Cells 2022; 45(9): 603-609 https://doi.org/10.14348/molcells.2022.0056